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Abstract Early ventricular fibrillation (EVF) predicts
mortality in ST-segment elevation myocardial infarction
(STEMI) patients. Data are lacking about prognosis and
management of non-ST-segment elevation myocardial
infarction (NSTEMI) EMI with EVF, especially at
higher age. In the daily clinical practice, there is no clear
prognosis of patients surviving EVF. The present study
aimed to investigate the risk factors and factors influenc-
ing the prognosis of NSTEMI patients surviving EVF,
especially at higher age. Clinical data, including 30-day
and 1-year mortality of 6179 NSTEMI patients, were
examined; 2.44% (n=151) survived EVF and were fur-
ther analyzed using chi-square test and uni- and multi-
variate analyses. Patients were divided into two age
groups below and above the age of 70 years. Survival
time was compared with Kaplan-Meier analysis. EVF
was an independent risk factor for mortality in NSTEMI
patients below (HR: 2.4) and above the age of 70 (HR:
2.1). Mortality rates between the two age groups of
NSTEMI patients with EVF did not differ significantly:
30-day mortality was 24% vs 40% (p=0.2709) and 1-
year mortality was 39% vs 55% (p=0.2085). Additional
mortality after 30 days to 1 year was 15% vs 14.6%
(p=0.9728). Clinical characteristics of patients with
EVF differed significantly from those without in both
age groups. EVF after revascularization—within 48 h—
had 11.2 OR for 30-day mortality above the age of 70.
EVF in NSTEMI was an independent risk factor for
mortality in both age groups. Invasive management
and revascularization of NSTEMI patients with EVF is
highly recommended. Closer follow-up and selection of
patients (independent of age) for ICD implantation in
the critical first month is essential.
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Introduction
Ventricular arrhythmias are potentially lethal complica-
tions of acute coronary syndromes. According to the
VALLIANT Trial, the risk of sudden cardiac death is
the highest within 1 month after the infarction [1]. Early
primary ventricular fibrillation (EVF) occurs within 48–
72 h after the symptoms’ onset and it is independent of
the reoccurring ischemia and heart failure. In daily clin-
ical practice, the prognosis of patients surviving EVF is
not clear.
However, the GISSI-2 Trial showed the relevance of
EVF as an independent predictor for in-hospital mortal-
ity [2]. Results regarding the risk factors and the effect
of EVF on the short- and long-term prognoses in ST-
segment elevation myocardial infarction (STEMI)
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patients have been controversial. EVF is a predictor for
both 30-day and 1-year mortality rates in STEMI pa-
tients treated with primary percutaneous coronary inter-
vention [3]. In contrast, another study suggested that
EVF was associated with higher in-hospital mortality
but did not affect the long-term prognosis [4]. Other
earlier studies also found non-significant impact of
EVF on prognosis [5], and recent studies did not con-
firm these results [6]. Medina-Rodriguez et al. found
that EVF before intensive care unit admission was an
independent predictor of in-hospital mortality in a co-
hort of patients in whom fibrinolysis was the main
method of revascularization therapy [7]. A similar prog-
nostic impact in patients treated with percutaneous cor-
onary intervention (PCI) was not present in that study,
suggesting that PCI has a long-term therapeutic benefit
in EVF patients. In a large unselected population of
STEMI patients treated with PPCI, ventricular fibrilla-
tion during the first 48 h after STEMI was associated
with increased in-hospital mortality but no influence on
the long-term prognosis for surviving patients was
established [8]. In contrast, Kosmidou et al. have report-
ed that ventricular arrhythmias occurring before coro-
nary angiography and revascularization in patients with
STEMI were strongly associated with an increased 3-
year likelihood of death and stent thrombosis [6].
Jabbari et al. investigated the independent risk factors
that contribute to the occurrence of ventricular fibrilla-
tion (VF) before PPCI in STEMI patients. They found
that traditional coronary artery disease (CAD) risk fac-
t o r s such a s d i abe t e s , hype r t en s i on , and
hypercholesterinemia did not predict risk while higher
age, family history of sudden cardiac death, use of
statins, and higher alcohol intake were independent risk
factors [9]. The extent of the CAD also contributed to
higher mortality. Larger studies found that EVF is asso-
ciated with the final infarct size [10, 11]. However, the
findings of Gheeraer et al. contradicted these results,
reporting that the region at risk and the site of the
occlusion are not independent risk factors for out-of-
hospital VF [12]. Literature data suggests that in
STEMI, EVF is an independent risk factor for in-
hospital and short-term mortality, and its effect on
long-term mortality is unclear.
Many previous studies have investigated the risk
factors contributing to EVF and the prognosis of EVF
in unselected myocardial infarction population. A high
proportion of acute coronary syndrome cases is
NSTEMI. In NSTEMI patients, the prognosis of EVF
and factors influencing the prognosis are less clarified.
NSTEMI patients are more likely to exhibit complicated
cases, have more comorbidities, and have higher mor-
tality rates in general. In addition, mean age in NSTEMI
is higher, and as a result of all these factors, it is essential
to evaluate this patient population. Since NSTEMI prev-
alence increases with age, the importance of evaluating
this patient population is particularly well justified. Cur-
rent guidelines have few instructions about the manage-
ment of NSTEMI patients with EVF, largely due to a
lack of study evaluation in this population, especially in
patients at higher age.
To help combat this lack of data about the prognosis
and management of NSTEMI patients surviving EVF,
the present study using our large database (~ 12,000
patients) has been undertaken. Our goal was to investi-
gate the risk factors contributing to early VF in the
elderly and identify factors influencing the prognosis
of NSTEMI subjects using a retrospective study design.
Methods
Study population and data collection
A total of 11,582 patients with acute coronary syndrome
have been revascularized between 2005 and 2013 at our
institution. These consecutive patients were enrolled in
the Városmajor Myocardial Infarction Registry
(VMAJOR-MI Registry), in which all the available
demographic data and clinical data are summarized.
Demographic data include gender, date of birth, date
of admission, and date of death. Clinical patient data
include laboratory findings (troponin T, CK-MB, creat-
inine, glucose, cholesterol, LDL-cholesterol), type of
infarction (STEMI, NSTEMI), results from echocardi-
ography, left ventricle ejection fraction (LV-EF), and
coronary angiography. The initiating acute event has
been characterized by the following factors: complicat-
ed by EVF, cardiogenic shock, on-site resuscitation,
heart failure, invasive respiratory treatment. Data from
EVF-positive patients was supplemented by informa-
tion on laboratory parameters such as potassium levels,
white blood cell (WBC) count, and C-reactive protein
(CRP) levels, as well as by information on detailed
coronary status such as the number of vessels affected,
and the number of vessels treated by PCI.
From this detailed VMAJOR-Registry, we enrolled
only patients having NSTEMI. Patients with ST-
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segment elevation myocardial infarction were excluded
from our analysis. We divided patients into two groups
based on whether or not their myocardial infarction led
to EVF. Patients were further grouped based on age
(above or below the age of 70 years). Figure 1 describes
the enrolment and grouping process in detail.
Diagnosis of NSTEMI was made based on typical
symptoms such as chest discomfort, upper extremity
discomfort, dyspnea, fatigue, and the elevation of ne-
crosis markers. EVF was defined as ventricular fibrilla-
tion requiring defibrillation in the first 48 h after AMI.
Patients in the EVF group included those who suffered
VF before or after revascularization as long as it was
within 48 h. Other types of ventricular arrhythmias, such
as ventricular tachycardia, were not examined.
Among NSTEMI patients, only patients undergoing
coronary angiography, defined as percutaneous coro-
nary intervention (PCI) in the first 12 h of symptom
onset, were included in the study [13]. Patients under-
going coronary artery bypass grafting surgery or who
were managed conservatively were not eligible for the
study. Coronary stenosis was evaluated frommultiplane
projections and a luminal diameter reduction of >50%
was considered significant. The study protocol
conformed to the ethical guidelines of the 1975 Decla-
ration of Helsinki and was approved in advance by the
locally appointed ethics committee (30088-2/2014/
EKU). The primary outcome of the study was all-
cause mortality. The National Health Care Institute pro-
vided accurate details on the above endpoint with oc-
currence dates.
Statistical methods
Analysis was performed using Statistica 13.2 software
and MedCalc statistical software. Continuous variables
were expressed as mean and standard deviation (mean ±
St. D); categorical variables were summarized as the
sample size (n) and frequencies. Student’s t-test was
used for comparison of normally distributed data and
Mann-Whitney U-test with non-normal distribution.
Categorical variables were compared using chi-square
test.
Cox proportional hazard model was used to identify
whether EVF was an independent risk factor for mor-
tality. The model included the general risk factors such
as age, gender, diabetes mellitus, left ventricle function,
severity of acute event—heart failure, cardiogenic
shock, invasive respiratory treatment—and EVF.
Cox regression analysis was performed in order to
identify clinical characteristics associated with mortali-
ty. The model included all available risk factors of acute
coronary syndromes and ventricular fibrillation such as
gender, age, body mass index (BMI), diabetes mellitus,
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Fig. 1 Process of patient
enrolment
GeroScience
LV-EF, complications of the acute event (on-site CPR,
cardiogenic shock, heart failure), coronary angiographic
results (coronary status—vessels affected, PCI results—
stent implantation on how many vessels), and the time
of the VF (before, during, or after the revascularization
but within 48 h). Hazard ratios (HR) with corresponding
95% confidence intervals (CI) were calculated using
Cox proportional hazard model. Survival time of the
different patient groups was compared using Kaplan-
Meier survival analysis. All statistical analysis was two-
tailed; the level of significance was p<0.05.
Results
The clinical characteristics of the 3140 NSTEMI pa-
tients below the age of 70 are presented in Table 1.
Significant differences were found between EVF-
positive and EVF-negative cases. EVF-positive
NSTEMI patients were more likely to have poor left
ventricle function (LV-EF <40%) (39.22% vs
14.95%), larger infarct size characterized by higher
troponin (2073.9 ng/L vs 902.3 ng/L), and higher CK-
MB (158.7 U/L vs 74.8 U/L), and were more likely to
have diabetes (55.56% vs 30.34%). They suffered
more severe infarction with more complications such
as cardiogenic shock (18.18% vs 2.15%) and in-
creased need for invasive respiratory treatment
(43.94% vs 5.6%). Given these significant differ-
ences, it is not surprising that EVF-positive patients
also had higher mortality rates than control patients.
30-day mortality was 24% vs 4.6% and 1-year mor-
tality was 39% vs 10.6% in EVF vs. non-EVF patients
<70, respectively. However, additional mortality
(mortality between 30 days and 1 year) did not differ
significantly.
Table 2 shows the differences between EVF and non-
EVF groups in patients above the age of 70 years. In the
older age group, similarly to the younger patient group,
subjects surviving EVF were more likely to have re-
duced left ventricle ejection fraction (44.4% vs 22.8%)
and diabetes (53% vs 37%). They also had more severe
complications after the acute event including cardiogen-
ic shock (18% vs 4%) and the need for invasive respi-
ratory treatment (56% vs 9%). As seen in the <70 patient
group, the patients aged >70 also exhibited increased
Table 1 Clinical characteristics of NSTEMI patients, differences between EVF-positive and EVF-negative patients
Characteristics of patients < 70 years
With EVF Without EVF p-value
Gender, male (%) 66.67% (44/66) 68.58% (2108/3074) 0.7871
Mean BMI (kg/m2) 29.2±6.4 28.75±5.5 0.564
LV-EF <40% (%) 39.22% (20/51) 14.95% (367/2455) 0.0041
Serum creatinine >100 umol/L (%) 39.68% (25/63) 20.56% (588/2860) 0.0223
Mean troponin T (ng/L) 2073.9±3219.1 902.3±1992.2 0.0006
Mean CK-MB (U/L) 158.7±195.2 74.8±94.3 <0.0001
DM (%) 55.56% (35/63) 30.34% (850/2802) 0.0016
Mean cholesterine (mmol/L) 4.65±1.5 4.79±1.4 0.4649
Mean LDL-cholesterol (mmol/L) 2.88±1.33 3.05±1.3 0.3811
Heart failure (%) 27.27% (18/66) 14.38% (442/3074) 0.132
Cardiogenic shock (%) 18.18% (12/66) 2.15% (66/3074) 0.0149
Resuscitation (%) 31.82% (21/66) 0.91% (28/3074) 0.0021
Invasive respiratory treatment (%) 43.94% (29/66) 5.6% (172/3074) <0.0001
Mean survival (days) 1587.9±1465.67 1924.5±1079.8 0.013
30-day mortality (%) 24.24% (16/66) 4.59% (141/3074) 0.0027
1-year mortality (%) 39.39% (26/66) 10.61% (326/3074) <0.0001
Mortality between 30 days and 1 year (%) 15.15% (10/66) 6.02% (185/3074) 0.2536
*p-value: difference between EVF-positive and EVF-negative NSTEMI patients. Statistical significant differences are highlighted in bold
Abbreviations: BMI, body mass index; LV-EF, left ventricle ejection fraction; DM, diabetes mellitus
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30-day and 1-year mortality in the EVF group vs non-
EVF group (40% vs 10% for 30 days and 55% vs 28%
for 1 year).
When we compared mortality rates for NSTEMI
patients surviving EVF in patients below 70 years vs
above 70 years, no significant difference has been found
in 30-day mortality (24% vs 40% p=0.2709), in 1-year
mortality (39% vs 55% p=0.2085), or in mortality be-
tween 30 days and 1 year (15% vs 14.6% p=0.9728).
EVF patients at younger (Fig. 2), as well as at older
age, >70 years (Fig. 3), had significantly (p<0.0001)
lower survival probability compared to non-EVF ones.
Figure 4 shows survival probability in the 4 patient
groups (based on age and EVF).
Table 2 Clinical characteristics of NSTEMI patients above the age of 70 years, differences between EVF-positive and EVF-negative
patients
Characteristics of patients > 70 years
With EVF Without EVF p-value
Gender, male (%) 64.63% (53/82) 52.96% (1548/2923) 0.094
Mean BMI (kg/m2) 26.6±4.4 27.1±4.8 0,4132
LV-EF <40% (%) 44.44% (32/72) 22.77% (529/2323) 0.0053
Serum creatinine >100 umol/L (%) 58.23% (46/79) 44.04% (1205/2736) 0.0574
Mean troponin T (ng/L) 1235.7±1695.8 841.1±1638.1 0.1232
Mean CK-MB (U/L) 103.5±94.8 77.3±94 0.0311
DM (%) 53.16% (42/79) 37.01% (989/2672) 0.0344
Mean cholesterol (mmol/L) 3.9±1.4 4.3±1,3 0.0167
Mean LDL-cholesterol (mmol/L) 2.3±1.3 2.6±1.2 0.0666
Heart failure (%) 40.24% (33/82) 26.27% (768/2923) 0.0762
Cardiogenic shock (%) 18.29% (15/82) 4.38% (128/2923) 0.0297
Resuscitation (%) 29.27% (24/82) 0.68% (20/2923) 0.0105
Invasive respiratory treatment (%) 56.1% (46/82) 8.93% (261/2923) <0.0001
Mean survival (days) 747.3±1026.9 n=82 1255.8±1032.3 <0.0001
30-day mortality (%) 40.24% (33/82) 10.20% (298/2923) <0.0001
1-year mortality (%) 54.88% (45/82) 28.26% (826/2923) 0.0001
Mortality between 30 days and 1 year (%) 14.63% (12/82) 18.06% (528/2923) 0.7597
p-value: difference between EVF-positive and EVF-negative NSTEMI patients. Statistical significant differences are highlighted in bold








Survival analysis of NSTEMI patients with and without EVF
below the age of 70 years










Fig. 2 Survival analysis of EVF-
positive compared to EVF-
negative NSTEMI patients below
the age of 70 years. Abbrevia-
tions: NSTEMI, non-ST-segment
elevation myocardial infarction;
EVF, early ventricular fibrillation
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Cox regression analysis showed that in patients <70,
EVF is an independent risk factor for all mortality (HR:
2.38) (Table 3), in addition to other factors such as
diabetes mellitus (HR: 2.02), heart failure (HR: 3.66),
cardiogenic shock (HR: 8.99), and invasive respiratory
treatment (HR: 5.4). Similarly, in patients above the age
of 70 years, EVF is also an independent risk factor for
mortality (HR: 2.1) as well as diabetes mellitus (HR: 1.5),
heart failure (HR: 2.4), cardiogenic shock (HR: 4.85), and
invasive respiratory treatment (HR: 3.2) (Table 4).
Seeing that EVF is an independent risk for mortality
in NSTEMI in both age groups, we furtherly evaluated
the risk factors for mortality in the NSTEMI with EVF
patient group. Factors influencing mortality in NSTEMI
patients surviving EVF are presented in Table 5. In
patients below the age of 70 years, these factors include
diabetes mellitus (HR: 1.9), cardiogenic shock (HR:
6.1), heart failure (HR: 2.65), and CPR (HR: 2.5).
However, at higher age (above 70 years), the only factor
influencing mortality was cardiogenic shock (HR: 2.3).
The extent of the coronary artery disease did not affect
mortality in either age group.
To help understand whether the timing of EVF, with
respect to the timing of the coronary revascularization,
had an effect on prognosis, we asked whether mortality
was different in patients who experienced EVF either
before or after PCI. In most cases in the <70 age group,
EVF developed before revascularization (75%, 51/68),
but the timing had no influence on either the short- or
long-term mortality (Table 6). In the higher age group
(>70 years), most EVF also developed before revascu-
larization (74%, 61/82). In contrast to the younger
group, in patients >70 years, EVF that occurs after
revascularization was associated with a higher risk of
30-day mortality (OR 11.2), although 1-year mortality







Survival analysis of NSTEMI patients with and without EVF
above the age of 70 years










Fig. 3 Survival analysis of EVF-
positive compared to EVF-
negative NSTEMI patients above
the age of 70 years. Abbrevia-
tions: NSTEMI, non-ST-segment
elevation myocardial infarction;







Survival analysis of NSTEMI patients 
with vs w/o EVF in both age groups
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Fig. 4 Survival analysis of EVF-
positive compared to EVF-
negative NSTEMI patients in
both age groups. Abbreviations:
NSTEMI, non-ST-segment ele-
vation myocardial infarction;
EVF, early ventricular fibrillation
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Discussion
According to the literature, the incidence of ventric-
ular arrhythmias including EVF in the acute phase of
MI is approximately 2–8% [7, 14], which is consis-
tent with data in our patient group resented here
(2.4%). Despite the fact that the incidence of ventric-
ular arrhythmias is higher in STEMI than in NSTEMI
(10% vs 2.1%) respectively [15], mortality rates in
the EVF patient group are significantly higher re-
gardless of the infarction type versus non-EVF pa-
tients. However, the FAST-MI program discovered
that 6-month mortality has decreased over the past 20
years [16]. Since 2010, mortality in STEMI patients
has continued to decline; however, mortality in
NSTEMI patients has remained stable [16],
highlighting the need for further investigation into
factors that affect NSTEMI mortality. In a small
group of invasively treated NSTEMI patients, Gupta
et al. investigated the incidence of and predictors for
malignant arrhythmias [17]. In their population, VF
occurred in 7.6% of the patients, a much higher
fraction than in our study in which 2.4% (151/6179)
experienced EVF. Similar to our study, they also
reported that 30-day mortality was significantly
higher in patients with vs. without VF (38% vs
3%), and their 30-day mortality rate among EVF
patients was comparable to what we observed
(33%). However, their EVF-negative patients had
higher 30-day mortality compared to our results de-
spite using invasive therapy. Similarly, Al-Khatib
et al. also reported increased 30-day and 6-month
mortality in spite of using effective therapy [15].
They found that in-hospital VF and VT were inde-
pendently associated with 30-day and 6-month mor-
tality even after excluding patients with heart failure
and cardiogenic shock and those who died within
24 h [15]. The MERLIN-TIMI 36 Trial also
highlighted the significance of non-sustained VT in
NSTEMI. Although non-sustained VT is common
after NSTEMI, short episodes of VT are indepen-
dently associated with a higher risk of sudden cardiac
death [18].
In the intervention era (2000–2012), the number of
patients who receive coronary angiography and PCI
after VT/VF has increased, resulting in a higher survival
rate—survival in all acute myocardial infarction has
risen from 46.9 to 60.1%, in STEMI survival has risen
Table 3 Cox regression analysis of factors influencing mortality in NSTEMI patients below the age of 70 years
Covariate HR 95% CI of HR p-value
LV-EF (%) 0.9549 0.9505 to 0.9593 <0.0001
Diabetes mellitus 2.0263 1.7685 to 2.3216 <0.0001
Cardiogenic shock 8.9915 6.9951 to 11.5577 <0.0001
Invasive respiratory treatment 5.4124 4.5299 to 6.4668 <0.0001
Heart failure 3.6573 3.1696 to 4.2201 <0.0001
Early ventricular fibrillation 2.3813 1.7133 to 3.3097 <0.0001
Abbreviations: LV-EF, left ventricle ejection fraction
Table 4 Cox regression analysis of factors influencing mortality in NSTEMI patients above the age of 70 years
Covariate HR 95% CI of HR p-value
BMI 0.9804 0.9693 to 0.9917 0.0007
LV-EF (%) 0.967 0.9633 to 0.9706 <0.0001
Diabetes mellitus 1.5217 1.3822 to 1.6754 <0.0001
Cardiogenic shock 4.8505 4.0652 to 5.7875 <0.0001
Invasive respiratory treatment 3.244 2.8442 to 3.7001 <0.0001
Heart failure 2.3965 2.1761 to 2.6392 <0.0001
Early ventricular fibrillation 2.1383 1.6780 to 2.7249 <0.0001
Abbreviations: BMI, body mass index; LV-EF, left ventricle ejection fraction
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from 59.2 to 74.3%, and in NSTEMI survival has risen
from 43.3 to 56.8% [19]. In spite of clear evidence
showing that coronary angiography and PCI increase
survival, in daily practice, some proportion of patients,
mostly NSTEMI, do not undergo revascularization. At
our high-volume cardiology institute with an invasive
approach, STEMI and NSTEMI patients are treated
invasively. Yet, in spite of this invasive strategy, here,
we report that NSTEMI patients surviving EVF still
have higher short- and long-term mortality rates com-
pared to those without EVF regardless of whether they
are above or below 70 years of age. Kaplan-Meier
analysis (Fig. 4) showed that in the first 3 years after
the acute myocardial infarction, younger patients with
EVF had worse survival probability than those older
ones without EVF. However, past the 3 years’ mark,
age becomes more important regards life expectancy.
This finding supports the fact that age is one of the main
determining factors of survival. Besides the clinical fact
that older patients are more likely to have numerous
comorbidities, cellular and molecular mechanisms may
contribute to increased mortality in older adults, e.g.,
impaired cellular stress and age-related oxidative stress.
Studies confirm this idea that hypoxia, oxidative stress,
worsens the prognosis of cardiovascular patients.
Trimetazidine was found to be a cytoprotective agent
[20] which improves the quality of life and left ventricle
function in elderly patients with ischemic heart disease
[21, 22]. Importantly, our analysis demonstrated that in
addition to other well-characterized comorbidities, EVF
is also an independent risk factor for mortality in both
age groups. This is consistent with other studies show-
ing that patients with EVF (compared to non-EVF pa-
tients) have more frequently reduced LV-EF and triple-
vessel coronary artery disease (CAD) resulting in higher
30-day mortality [23]. Interestingly, the prognosis had
no correlation with the extent of the coronary artery
disease either at lower or at higher age in NSTEMI
Table 5 Cox regression analysis of factors influencing mortality in NSTEMI patients surviving EVF
NSTEMI patients surviving EVF below the age of 70 NSTEMI patients surviving EVF above the age of 70
Covariate HR 95% CI of HR p-value Covariate HR 95% CI of HR p-value
LV-EF (%) 0.9506 0.9226 to 0.9795 0.0009 LV-EF (%) 0.9716 0.9503 to 0.9934 0,011
Diabetes mellitus 1.9262 1.2884 to 2.8797 0.0014 Diabetes mellitus 1.467 0.8977 to 2.3974 0.1262
Cardiogenic shock 6.1416 2.9553 to 12.7635 <0.0001 Cardiogenic shock 2.3205 1.2655 to 4.2551 0.0065
Heart failure 2.6468 1.3432 to 5.2154 0.0049 Heart failure 1.3306 0.8119 to 2.1807 0.2571
CPR 2.5042 1.3009 to 4.8206 0.006 CPR 1.0754 0.6297 to 1.8368 0.7901
2-vessel disease* 1.2863 0.5665 to 2.9207 0.5473 2-vessel disease* 1.1272 0.6895 to 1.8427 0.6330
3-vessel disease* 2.1285 0.8956 to 5.0583 0.0872 3-vessel disease* 1.7589 0.9067 to 3.4119 0.0948
Abbreviations: LV-EF, left ventricle ejection fraction; CPR, cardiopulmonary resuscitation
*Compared to 1-vessel disease based on coronary angiographic results
Table 6 The effect of the EVF’s occurrence on the 30-day and 1-year mortality in all NSTEMI patients
Total Dead % p OR OR 95% CI
30-day mortality in patients below the age of 70
VF during rev.* 12 1 8.33 -
VF before rev.* 51 13 25.49 0.1984 0.2657 0.0312–2.2626
VF after rev.* <48 h 5 2 40 0.1186 7.3 0.4836–111.19
1-year mortality in patients below the age of 70
VF during rev.* 12 2 16.67 -
VF before rev.* 51 22 43.14 0.0893 0.2636 0.0524–1.327
VF after rev. <48 h* 5 2 40 0.3014 3.33 0.319–34.83
*rev., revascularization
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patients surviving EVF. In NSTEMI patients with EVF
at younger age, several factors had an influence on
mortality, such as LV-EF, diabetes mellitus, cardiogenic
shock, heart failure, and on-site resuscitation. In contrast
to that at higher age, the only factor was a cardiogenic
shock.
One interesting finding of our study was the timing of
EVF (with respect to the timing of intervention) impact-
ed the prognosis in older but no younger NSTEMI
patients. The impact of timing on outcomes has also
been examined by others. For example, according to
Jabbari et al., there is no difference in the 30-day mor-
tality in STEMI patients depending on VF before or
during PCI [24].
In general, NSTEMI patients have worse prognosis
than STEMI patients, and cases that are complicated
with EVF have even poorer outcomes. The mortality
risk was the highest within the first 30 days; we found
that 40% of the aged patients died within the first month.
There are only a few differences in clinical factors
influencing who will develop EVF in the two age
groups. The fact that EVF develops based on acute
myocardial ischemia is not surprising. Our results sug-
gest that this pathomechanism is the same at higher age.
Invasive management of NSTEMI patients is essential,
and even with invasive management, EVF was an inde-
pendent risk factor for mortality. These findings suggest
that closer follow-up—using telemedicine in the aged
patient population with decreased mobility—in the crit-
ical first 30 days is essential. It is important to select
patients, independently from age, who would benefit
from an early implantable cardioverter-defibrillator im-
plantation before discharge. With more outpatient visits,
more precise medication setup for secondary prevention
would be beneficial independently from age.
Limitation section
The present study was a single-center retrospective ob-
servational study with limited available data. Factors
affecting the prognosis such as ICD implantations, med-
ication intake, and compliance could not be
investigated.
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Table 7 The effect of the EVF’s occurrence on the 30-day and 1-year mortality in NSTEMI patients above 70 years
Total Dead % p OR OR 95% CI
30-day mortality above the age of 70
VF during rev.* 9 1 11.11% -
VF before rev.* 61 25 40.98% 0.0834 0.18 0.021–1.53
VF after rev.* <48 h 12 7 58.33% 0.027 11.2 1.04–120.4
1-year mortality above the age of 70
VF during rev.* 9 4 44.44% -
VF before rev.* 61 32 52.46% 0.653 0.725 0.177–2.962
VF after rev. <48 h* 12 9 75% 0.153 3.75 0.587–23.94
*rev., revascularization
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